NASDAQ
DFFN

Diffusion Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Diffusion Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$5.0715
Today's High:
$5.35
Open Price:
$5.0715
52W Low:
$3.55
52W High:
$8.74
Prev. Close:
$5.18
Volume:
9611

Company Statistics

Market Cap.:
$7.41 million
Book Value:
7.98
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-27.86%
Return on Equity TTM:
-64.64%

Company Profile

Diffusion Pharmaceuticals Inc had its IPO on 2016-01-04 under the ticker symbol DFFN.

The company operates in the Healthcare sector and Biotechnology industry. Diffusion Pharmaceuticals Inc has a staff strength of 13 employees.

Stock update

Shares of Diffusion Pharmaceuticals Inc opened at $5.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.07 - $5.35, and closed at $5.3.

This is a +2.32% increase from the previous day's closing price.

A total volume of 9,611 shares were traded at the close of the day’s session.

In the last one week, shares of Diffusion Pharmaceuticals Inc have slipped by -10.47%.

Diffusion Pharmaceuticals Inc's Key Ratios

Diffusion Pharmaceuticals Inc has a market cap of $7.41 million, indicating a price to book ratio of 0.5113 and a price to sales ratio of 0.

In the last 12-months Diffusion Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15878764. The EBITDA ratio measures Diffusion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Diffusion Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -27.86% with a return of equity of -64.64%.

In Q1, Diffusion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Diffusion Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-7.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Diffusion Pharmaceuticals Inc’s profitability.

Diffusion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.6498. Its price to sales ratio in the trailing 12-months stood at 0.

Diffusion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.40 million
Total Liabilities
$2.13 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Diffusion Pharmaceuticals Inc ended 2024 with $18.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.40 million while shareholder equity stood at $16.28 million.

Diffusion Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $2.13 million in other current liabilities, 2040.00 in common stock, $-149688923.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.65 million and cash and short-term investments were $17.64 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Diffusion Pharmaceuticals Inc’s total current assets stands at $18.40 million while long-term investments were $0 and short-term investments were $2.99 million. Its net receivables were $0 compared to accounts payable of $971455.00 and inventory worth $0.

In 2024, Diffusion Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Diffusion Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.3
52-Week High
$8.74
52-Week Low
$3.55
Analyst Target Price
$24.75

Diffusion Pharmaceuticals Inc stock is currently trading at $5.3 per share. It touched a 52-week high of $8.74 and a 52-week low of $8.74. Analysts tracking the stock have a 12-month average target price of $24.75.

Its 50-day moving average was $5.08 and 200-day moving average was $7 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.

Around 24.1% of the company’s stock are held by insiders while 931.8% are held by institutions.

Frequently Asked Questions About Diffusion Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Diffusion Pharmaceuticals Inc is DFFN

The IPO of Diffusion Pharmaceuticals Inc took place on 2016-01-04

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$7.73
-0.09
-1.15%
$123.3
-9.45
-7.12%
$373.4
-23.75
-5.98%
BEML Limited (500048)
$2310.85
-294.55
-11.31%
$1.3
-0.11
-7.8%
$440.4
-10.95
-2.43%
$1683.05
12.88
+0.77%
$1.34
-0.06
-4.29%
$8.64
0.04
+0.47%
$73.83
-1.5
-1.99%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Address

300 East Main Street, Charlottesville, VA, United States, 22902